Truist Securities Maintains Buy on Upstream Bio, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Negative 73.8%

Neg 73.8% Neu 0% Pos 0%

Truist Securities analyst Danielle Brill maintains Upstream Bio (NASDAQ:UPB) with a Buy and lowers the price target from $43 to $25.